109 related articles for article (PubMed ID: 9024071)
1. Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma.
Googe PB; McGinley KM; Fitzgibbon JF
Am J Clin Pathol; 1997 Feb; 107(2):219-23. PubMed ID: 9024071
[TBL] [Abstract][Full Text] [Related]
2. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.
Wojno KJ; Epstein JI
Am J Surg Pathol; 1995 Mar; 19(3):251-60. PubMed ID: 7532918
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland.
O'Malley FP; Grignon DJ; Shum DT
Virchows Arch A Pathol Anat Histopathol; 1990; 417(3):191-6. PubMed ID: 1696762
[TBL] [Abstract][Full Text] [Related]
6. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical analysis with anti-cytokeratin antibody in the prostatic epithelium].
Yamanaka Y; Ishida H; Okada K; Nemoto N
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):545-53. PubMed ID: 11517564
[TBL] [Abstract][Full Text] [Related]
8. Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate.
Shin M; Fujita MQ; Yasunaga Y; Miki T; Okuyama A; Aozasa K
Int J Urol; 1998 May; 5(3):237-42. PubMed ID: 9624554
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of prostate carcinoma on biopsy specimens improved by basal-cell-specific anti-cytokeratin antibody (34 beta E12).
Freibauer C
Wien Klin Wochenschr; 1998 Sep; 110(17):608-11. PubMed ID: 9816630
[TBL] [Abstract][Full Text] [Related]
10. Screening for occult nodal metastasis in localized carcinoma of the prostate.
Gomella LG; White JL; McCue PA; Byrne DS; Mulholland SG
J Urol; 1993 Apr; 149(4):776-8. PubMed ID: 7681116
[TBL] [Abstract][Full Text] [Related]
11. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer.
Yang XJ; Lecksell K; Gaudin P; Epstein JI
Am J Surg Pathol; 1999 Feb; 23(2):147-52. PubMed ID: 9989840
[TBL] [Abstract][Full Text] [Related]
12. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies.
Abrahams NA; Ormsby AH; Brainard J
Histopathology; 2002 Jul; 41(1):35-41. PubMed ID: 12121235
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
14. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.
Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO
Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227
[TBL] [Abstract][Full Text] [Related]
15. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
16. Detection of occult metastases in pancreatic adenocarcinoma with anticytokeratin antibody.
Tian F; Myles JL; Appert HE; Kim K; Howard JM
Pancreas; 1992; 7(2):159-64. PubMed ID: 1372737
[TBL] [Abstract][Full Text] [Related]
17. [Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S].
Xiao Q; Yin H; Lu Z; Meng K; Zhou X
Zhonghua Nan Ke Xue; 2004 May; 10(5):362-5. PubMed ID: 15190830
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of restaining prostate needle biopsies with high-molecular weight cytokeratin.
Dardik M; Epstein JI
Hum Pathol; 2000 Sep; 31(9):1155-61. PubMed ID: 11014585
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining with cytokeratin combining semi-serial sections for detection of cervical lymph node metastases of oral squamous cell carcinoma.
Guo CB; Li YA; Gao Y
Auris Nasus Larynx; 2007 Sep; 34(3):347-51. PubMed ID: 17399927
[TBL] [Abstract][Full Text] [Related]
20. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma.
Okada H; Tsubura A; Okamura A; Senzaki H; Naka Y; Komatz Y; Morii S
Virchows Arch A Pathol Anat Histopathol; 1992; 421(2):157-61. PubMed ID: 1381129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
